Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Efudex Articles

R-PR's Irinotecan And Colorectal Cancer

13 February 1995

R-PR Submits First Licence Application For Irinotecan

2 January 1995

Phase II Results With Zeneca's Tomudex

28 November 1994

Lilly's Gemcitabine; First Phase III Results

28 November 1994

Euro CPMP Views Janssen Drug

7 November 1994

Nippon Shoji "Aware of Usevir Effects"

22 August 1994

NICOTINE PATCH AND SKIN TOXICITY

27 June 1994

CONFERENCE REPORT: ASCO MEETING

30 May 1994

TAXOTERE REVEALS BROAD ACTIVITY

23 May 1994

MATRIX ANTICANCER GEL: PRECLIN DATA

9 May 1994

MORE ON NETIVUDINE WITHDRAWAL

4 April 1994

NEW TRIAL DATA ON R-PR'S TAXOTERE

21 March 1994

IMMUNEX AIMS FOR THREE DRUGS IN CLINIC IN 1994

21 February 1994

IRINOTECAN BACKED IN JAPAN AMID CONCERNS

13 December 1993

USEVIR PULLED AS DEATHS FOLLOW LAUNCH

25 October 1993

EC CPMP DIVIDED ON LEVAMISOL APPROVAL

28 June 1993

PALA DOES NOT ENHANCE 5-FU

31 May 1993

PHASE II TRIALS OF MPI 5003 STARTED

31 May 1993

EXPANDING USES FOR INTERFERON ALPHA

31 May 1993

GLAXO COMPROMISES OVER ONDANSETRON PATENT

26 April 1993

PROFITS FALL AT KYOWA HAKKO

22 March 1993

WORLD ANTICANCER/ IMMUNOLOGY MARKET

8 February 1993

PHASE II RESULTS WITH MPI 5003

14 December 1992

J&J'S LEVAMISOLE "OVERPRICED"

1 June 1992

FRENCH FOLINIC ACID STUDY

13 April 1992

FRENCH FOLINIC ACID STUDY

13 April 1992

Showing 201-226 of 226 articles

Go to beginningPrevious
  • 1
  • 2
  • 3
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS